Navigation Links
MetaStat, Inc. Executes Two New Licenses
Date:4/27/2012

of anti-metastatic drugs. There are currently no FDA approved drugs to target and kill these metastatic cells.

"Isolation, Gene Expression, and Chemotherapeutic Resistance of Motile Cancer Cells" describes an "artificial blood vessel" that was developed to mimic the chemical attraction exerted on highly metastatic cells by the tumor vasculature. We believe this is the first method available to actually isolate, collect, genetically profile, and determine chemotherapeutic resistance of a pure population of metastatic cancer cells from a tumor. Previously, attempts to genetically profile these dangerous cells were difficult because tumor samples available for analysis contained large proportions of proliferative and structural cells and only a tiny proportion of metastatic cells.

"Human Invasion Signature for Prognosis of Metastatic Risk," another result of our proprietary ability to isolate metastatic cells, describes the actual causative gene signature of metastatic cells. This approach contrasts with currently available technology that purports to evaluate risk of cancer recurrence by relying upon correlative mathematical algorithms developed through the statistical analysis of whole tumor tissue samples.

About MetaStat, Inc.

MetaStat is a life science company focused on the development and commercialization of proprietary clinical diagnostic tests that predict the probability of systemic hematogenous (blood borne) metastasis of cancer, as well as companion therapeutics to prevent this deadly spread. We believe our initial product, the MetaSite Breast™ test, will predict the probability that cancer will be disseminated by this means to other organs in the body. MetaSite Breast is expected to be an important guide to treatment strategies for breast cancer patients and their doctors because metastasis is responsible for almost 90% of fatalities from breast cancer.  Further, the platform technology underlying thi
'/>"/>

SOURCE MetaStat, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. PhotoVoltaic Solar Cells, Inc. Completes Share Exchange with MetaStat, Inc.
2. MetaStat, Inc. Completes Share Exchange with PhotoVoltaic Solar Cells, Inc.
3. Ampio Pharmaceuticals Executes License and Development Agreement with Daewoong Co. Ltd. to Commercialize Zertane™ in South Korea
4. Adeona Executes Agreement to Initiate Phase IIb Clinical Trial of Proprietary Zinc-Based Therapy in Lou Gehrigs Disease (ALS)
5. Adeona Executes Manufacturing and Supply Agreement with TG United for reaZin™
6. Soligenix Executes Exclusive License with the University of Colorado for Vaccine Thermostabilization Technology
7. Alexza Executes $15 million Working Capital Loan with Hercules Technology Growth Capital, Inc.
8. Kun Run Biotechnology, Inc. Executes Purchase Agreements for Approximately $8 Million Private Placement
9. Obecure Executes Licensing and Clinical Supply Agreement With Farmaceutici-Formenti SPA for Extended Release Formulation of Betahistine
10. Transgenomic, Inc. Executes License Option agreement for Parkinsons Disease Diagnostic Markers with Gene Solutions, LLC
11. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... -- Decision Resources Group finds that, for the treatment ... France , Germany , ... and the United Kingdom ) hold ... beta2 agonist/inhaled corticosteroid (LABA/ICS) fixed-dose combination (FDC), Relvar (GlaxoSmithKline/Theravance). ... first-line LABA/ICS FDC in the treatment of asthma with ...
(Date:7/24/2014)... , July 24, 2014 /PRNewswire-iReach/ -- "North America ... key market data on the North America Orthopedic Braces ... of US dollars, and volume (in units) and average ... , Knee Braces and Supports , Ankle ... , Upper Extremities Braces and Supports. ...
(Date:7/24/2014)... 24, 2014 Boston Children,s Hospital,s Global Pediatric ... will feature an "Innovation Tank" – a forum designed ... pitch their business or product solution to a panel ... on how to accelerate the innovation and bring it ... of Friday, October 31, will be moderated by ...
Breaking Medicine Technology:Surveyed EU5 Pulmonologists Expect that Relvar, the First Once-Daily LABA/ICS FDC, Will Experience Healthy Uptake in Asthma 2Surveyed EU5 Pulmonologists Expect that Relvar, the First Once-Daily LABA/ICS FDC, Will Experience Healthy Uptake in Asthma 3North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 2North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 3North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 4North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 5Taking on Tomorrow to Feature "Innovation Tank" Pitch Opportunity for Aspiring Pediatric Health Care Entrepreneurs 2Taking on Tomorrow to Feature "Innovation Tank" Pitch Opportunity for Aspiring Pediatric Health Care Entrepreneurs 3
... 2011 /PRNewswire-Asia-FirstCall/ -- Financial Highlights for the ... increased 40.8% to $7.68 million Gross profit increased 30.1% to ... 14.2% to $3.90 million, representing a net margin of 50.8% ... Financial Highlights for the Six Months Ended June ...
... Mylan Inc. (Nasdaq: MYL ) today announced that ... Tablets, 10 mg. This product is the generic version of ... hyperplasia, or an enlarged prostate. Uroxatral® Tablets ... months ending June 30, 2011, according to IMS Health. ...
Cached Medicine Technology:Nutrastar Announces Second Quarter 2011 Financial Results 2Nutrastar Announces Second Quarter 2011 Financial Results 3Nutrastar Announces Second Quarter 2011 Financial Results 4Nutrastar Announces Second Quarter 2011 Financial Results 5Nutrastar Announces Second Quarter 2011 Financial Results 6Nutrastar Announces Second Quarter 2011 Financial Results 7Nutrastar Announces Second Quarter 2011 Financial Results 8Nutrastar Announces Second Quarter 2011 Financial Results 9Nutrastar Announces Second Quarter 2011 Financial Results 10Nutrastar Announces Second Quarter 2011 Financial Results 11
(Date:7/24/2014)... July 24, 2014 Dr. Kwame Bawuah ... the workshop with an admonition to the youth to ... in life. He also advised the youth to stay ... sex. He said, “This workshop will afford you the ... you to withstand the storms in your career path.” ...
(Date:7/24/2014)... 24, 2014 The first-ever successful isolation ... patient’s blood has been achieved by NFCR-supported scientist Daniel ... Hospital. This is an important milestone on the road ... the best treatment for each patient. , “Tumors ... often acquire new genetic features that make them resistant ...
(Date:7/24/2014)... the patient or their tumor more directly to ionizing ... damages the cancer cells irreparably. Unfortunately, such radiation is ... the site of the tumor, which is then at ... cancer. As such finding ways to protect the overlying ... Journal of Low Radiation, Faruck Lukmanul Hakkim of the ...
(Date:7/24/2014)... have uncovered a way the malaria parasite becomes ... Washington University School of Medicine in St. Louis, ... bacterial infections and tuberculosis. , The study appears ... Many organisms, including the parasite that causes malaria, ... play multiple roles in keeping organisms healthy, whether ...
(Date:7/24/2014)... Charlotte, NC (PRWEB) July 24, 2014 ... donated over $138,000 in sealant and anesthesia reversal ... ToothFairy® (NCOHF) to help save young smiles. The ... Sealant Kits and Oraverse® was distributed to America’s ... the U.S. with vital oral health services. The ...
Breaking Medicine News(10 mins):Health News:Youth and Professionals Interact at Washington Metro Area Career Workshop Hosted by the Edusei Foundation 2Health News:New Blood Test Advances Individualized Cancer Therapy and Cuts Down on Need for Painful Biopsies 2Health News:Natural products from plants protect skin during cancer radiotherapy 2Health News:One route to malaria drug resistance found 2Health News:One route to malaria drug resistance found 3Health News:Septodont Donation Helps Children in Need 2
... responsible for a form of the herpes virus that causes ... causes purple skin blotches and can also attack the internal ... disease defenses but attacks those with weakened immune system as ... 8 was discovered six years ago. Almost 30% to 50% ...
... not reduce ,the risk of cardiac events ... disease (CAD). In the PHASE trial (Papworth ... women with angiographically proven coronary ,artery disease ... without cyclic norethisterone--or no hormone replacement therapy. ...
... Lunelle-a monthly injectable contraceptive pill has been approved by ... is more than 99 percent effective when women get ... release marketing the pill., ,Lunelle is an alternative ... months. It works Like many other birth control pills ...
... overall long-term survival rates in both men and women. Their ... ,Researchers studied survival rates based on a lung function ... the lung function test on a group of more than ... age from 20 to 89 years at enrollment. They have ...
... In some of the cancer patients the Tumors can't be ... using vitamin B12 that helps doctors locate hard to find ... vitamin B12. After three hours a gamma camera takes pictures ... cancer and he says that, "The cancer stands out as ...
... The American Heart Association announced it has revised ... of ,cardiovascular emergencies., ,Untrained bystanders and CPR-certified ... an unconscious person's pulse before administering chest compressions. ... breath, movement and response to stimulation as indicators. ...
Cached Medicine News:
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: